Kromek Share Price (KMK)

Trade Now

 Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Kromek Group Plc LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
Upgrade Icon
  -0.40 -4.62% 8.25 750,613 09:53:42
Bid Price Offer Price High Price Low Price Open Price
8.10 8.40 8.65 8.25 8.65
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.06 -6.13 -1.10 36
Last Trade Time Trade Type Trade Size Trade Price Currency
13:30:05 O 30,000 8.166 GBX
Related Shares
Astrazeneca (AZN), Gsk (GSK), N4 Pharma (N4P), Bermele (BERM)

Kromek (KMK) Latest News (1)

Kromek News

Date Time Source Headline
28/9/202212:27UKREGKromek Group PLC Result of AGM
02/9/202219:51UKREGKromek Group PLC Notice of AGM and Publication of Annual Report
02/9/202217:26UKREGKromek Group PLC Notice of AGM and Publication of Annual Report
23/8/202212:03ALNCNewsKromek Group raises GBP1.1 million in convertible loan notes
23/8/202211:10UKREGKromek Group PLC Fundraising of GBP1.14 million
05/8/202211:58ALNCNewsKromek shares jump following GBP1.7 million fundraise
05/8/202207:00UKREGKromek Group PLC Fundraising of GBP1.7m
03/8/202214:05UKREGKromek Group PLC Second Price Monitoring Extn
03/8/202214:00UKREGKromek Group PLC Price Monitoring Extension
02/8/202212:13ALNCNewsEARNINGS UPDATES: RIT Capital outperforms index; Smithson NAV drops
More Kromek News
Kromek Investors    Kromek Takeover Rumours

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
28/9/202213:40Kromek Group PLC6,411
05/1/202209:19Kromek Group (KMK) - Overvalued AIM mugging182

Add a New Thread

Kromek (KMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:30:068.1730,0002,449.80O
12:24:588.3024,0961,999.97O
12:24:088.3010,000830.00O
10:21:138.31120,1939,988.04O
10:05:358.1552,0044,235.73O
View all Kromek trades in real-time

Kromek (KMK) Top Chat Posts

Top Posts
Posted at 28/9/2022 09:20 by Kromek Daily Update
Kromek Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 8.65p.
Kromek Group Plc has a 4 week average price of 8.25p and a 12 week average price of 8.25p.
The 1 year high share price is 17.90p while the 1 year low share price is currently 7.95p.
There are currently 431,851,820 shares in issue and the average daily traded volume is 540,649 shares. The market capitalisation of Kromek Group Plc is £35,627,775.15.
Read Full Thread
Reply
Posted at 06/9/2022 22:35 by mjneish
2) Even better, please clarify. Resolution 9 of the 2020 AGM authorised Kromek to buy back up to 34,489,709 shares from the market down to a price of 1p and at no more than 5% above the market price. https://www.kromek.com/wp-content/uploads/2020/10/2020-Notice-of-AGM.pdf - Did Kromek subsequently buy back any shares? - Did the share price go down to 1p as a result of this resolution?
Read Full Thread
Follow
Reply
Posted at 10/8/2022 03:36 by ark87
The shareprice was down until IC tipped it (again). Unfortunately as you can see from KMK share price performance since inception (51p to to 14p over 9 years) will be short lived unless some game changing news is on horizon which at this point seems doubtful.
Read Full Thread
Follow
Reply
Posted at 06/8/2022 20:04 by strategicinvestor2
Suspect we will have further announcements as contracts going through legals are finalised, hopefully push share price back to the 21-22p level where it showed resistance historically. ?? Any views on share price triggers ?? IMHO DYOR
Read Full Thread
Follow
Reply
Posted at 05/8/2022 13:52 by aqc888
It’s all a bit mysterious with Kromek. I find it a very interesting one to watch. However the deeds of the CEO speak far louder than his words throughout the history of Kromek. By that I mean his purchase of shares remains very little, as the share price collapses he should take the opportunity to buy a significant amount - that’s if he believes his view of how great things are going to be. The share ownership of the ceo has tipped my view into believing the worst. It’s with great disappointment I sell a big chunk of my remaining Kromek, especially as someone who once believed so much in Kromek I allocated 10% of my portfolio in it (reduced to 2% at 16p). The CEOs decision not to invest has been the correct one looking at Kromeks history. His continued decision not to invest would seem to be the clearest indication of where Kromeks future lies and whether the current share price weakness is a bargain or not. He should lead with his actions as the share price collapses. That’s just my personal view of what a founder & CEO should do if his share price is collapsing and he genuinely believes the market has got it wrong. Perhaps a bit of an unfair view…
Read Full Thread
Follow
Reply
Posted at 16/5/2022 11:24 by charlie_bucket
I believe cash of £5.1m mentioned is gross cash. Net cash after deducting borrowings will be lower, maybe even negative. Borrowings were £6.8m in the interims, and cash was £10.2m. Does look to me like shareholder money is being spent on research papers in getting that share price up so that they can get shares away without being hugely diluting. And with no directors using their own money to buy shares to try and have the same effect. Say they want to raise £15m plus fees. Current market cap is £35m at price of 8 pence. That’s 200 million new shares, nearly half as many as now in issue! I think existing and new shareholders need to be careful. Despite the technology and products’ potential and the progress being made, I believe this can still go down further and even to zero if they can’t raise more equity capital particularly if the overall market has a sharp downturn. Ask yourself: are the same institutions who bought in at 15 pence last time going to double down and buy more at a lower share price when they are holding a loss in these market conditions? Has what the company said last time come true? Or are the institutions going to invest elsewhere? Another point is that I believe a “clean” audit report for the year end accounts without a “going concern” qualification would depend on new equity funding being in place to guarantee trading for the 12 months after the issue of the annual accounts later this year. All just my opinions, need to do your own research and come to your own.
Read Full Thread
Follow
Reply
Posted at 14/2/2022 12:19 by ark87
KMK share price also looks to be entering very dangerous times.
Read Full Thread
Follow
Reply
Posted at 27/1/2022 14:24 by charlie_bucket
As a counterweight to the optimism from AQC888 and others: A concern of mine is that the company is looking for a short term boost to the share price before announcing a placing / cash raise again soon. Particularly helpful if the share price rises on the back of another Simon Thompson recommendation. This is still very much a loss making company which will need future cash raises – despite talk of “cash profit” or “Adjusted EBITDA” – since revenue isn’t high enough yet to break even, plus development costs go to the balance sheet and don’t get deducted until later in the P&L. For last 6 months just published, loss before tax was £3.1m but that’s after forgiveness of COVID loans (£1.3m) and £3.1m of R&D costs capitalized which was higher than the R&D cost amortization (£1.0m). If my thinking here is correct, that makes £6.5m underlying cash outflow (excl. tax) for a half year. They had cash balance of £10.2m end of October minus £4.8m short term borrowings, so £5.4m net cash. Timing of placing announcement last year was 12th February, and share price fell about 15% on day of announcement. Now could be the time of year that they think about another one.
Read Full Thread
Follow
Reply
Posted at 04/1/2022 19:55 by aqc888
Two weeks today we’ll have the interim results. Here are my predictions: 1)A government order has been received and they are continuing discussions with multiple other governments. Kromeks share price goes stratospheric, hit the headlines and see share price go beyond 80p within a week. It would eclipse the rest of the business. My assessment of this is a 35% chance. 2)Kromeks main business is slightly ahead of analysts forecasts and they are close to finalising deals with the biological pathogen detector. Even though we all know this to be the case already, as the ceo has already said this. When it’s announced with the interim results it’s likely to cause some excitement and share price will get close to 28p. My assessment of this is 35%. However, importantly in this scenario the Simon Thompson card will be played 3weeks later. I think this scenario will almost certainly mean Kromek will be included in his much awaited bargain shares edition which will see it surge from under 30p to nearing 50p. 3)Kromeks main business is slightly ahead of forecasts and very vague news about the biological pathogen detector. 15% chance. Share price will move marginally up or down. 4)Kromeks main business is more or less in line with forecasts and slightly negative news on biological pathogen detector. 10% chance. Share price back down to 13-15p. 5)Kromeks main business underperforming and no news of biological pathogen detector. 5% chance. Share price down to 10-12p. Wildcards - they’ve received bids for part of all of business. 5% chance. Share price up to 50p A lot of upside here in my opinion. Looking forward to the results... Not far off reaching highs of 18p before interim results from last forecast when share price was 14.5p...
Read Full Thread
Follow
Reply
Posted at 20/12/2021 19:25 by aqc888
Boomboy, you need to wait for the interim results and news of the biological pathogen detector. All the ups and downs upto that point will be overturned by these results. I’m still confident Kromek will be included in Simon Thompson’s small cap bargain shares in the early feb edition. If he thought it was a strong buy 6-12months ago then right now there is positive news coming in all directions and segments, it will gain anything from 20-40% on the day if it’s included. Forget the share price, look at the business and each segment, to recap; Nuclear detectors Kromek should be a beneficiary of the UK Government’s £329m five-year nuclear detection budget, given that Kromek’s product offering covers key areas of border control and terrorism threat detection – its dirty bomb detectors are now deployed in 26 countries – and the UK Government is “localising supply chains.” Basu revealed that Kromek has £20m worth of revenue in active procurement in the nuclear sector that “could be delivered this year”, highlighting the marked increase in activity being seen across major international markets. CZT scanners; They had that ‘upto’ £17m contract. Plus news reports show hospitals delayed scanner replacement during pandemic and a strong market was forecast here. There’s also the new breast cancer scanners and baggage / industrial use new orders. Biological pathogen detector; We all know about this positive news on the horizon... 2022 seems like the year it’s all going to come together. Will be a good inclusion in Simon Thompson’s February edition and hopefully perform as well as similar IP heavy, share price weak, company Xaar last year. Which went from 42p (in his feb 2020 list) to highs of 240 or 169p today. Kromek reaching highs of 60-80p in the next few years wouldn’t be so extraordinary. After all a share price at that level could still be seen as a bargain considering the price of rival CZT scanner company to Canon last year - plus all the other segments of Kromek. Things have the potential to turn around very dramatically here. I’m increasingly confident.
Read Full Thread
Follow
Reply
Posted at 05/12/2021 07:32 by charlie_bucket
If you own shares in Kromek as I see it you've bought a lottery ticket (bio-security) on top of a regular investment (nuclear, medical). For bio-security, think in probabilities. First order sizes could be very big. Very big number times % probability still equals big number. That's how to value the impact on the shares. Just because they haven't announced any sales of bio-security products yet doesn't mean they are failing, but says that they're still working on making those lottery numbers come up. You can question whether the CEO is the right man for all this commercially, I share the same concerns. I think that’s already factored into the current share price. Clearly he's technically strong which is good because if these products don't work then you're not selling any at all. If he gets enough advice and door-opening from others (chairman, bought-in consultants) then that can compensate. And yes, loss-making businesses do need to raise more funds sometime in the future, that just goes with the territory. If shareholders think the share price is good value vs the future profit potential, then they'll pay up and on we go. In the meantime you have an established and growing business with strong products and growth in the other areas (nuclear, medical) that might even justify the current share price on their own and give protection to share price on downside.
Read Full Thread
Follow
Reply
Kromek share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
KMK
Kromek
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220928 13:09:05